Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics

Usman, Sani Sharif; Uba, Abdullahi Ibrahim; Christina, Evangeline

doi:10.1007/s11033-023-08557-4

Cited by 9 publications

(2 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, biofilm‐associated infections can have a serious impact on health, making the diagnosis and treatment of biofilms challenging (Pai et al, 2023 ). One of the most promising therapeutic alternatives to antibiotics for treating these forms of bacterial resistance is bacteriophage‐based therapy (Usman et al, 2023 ). Bacteriophages (Figure 4 ) are viruses that exclusively infect bacteria and are among the most numerous, diverse, and dynamic biological entities on this planet (Fogg et al, 2017 ).…”

Section: Bacteriophage‐based Therapies To Combat Forms Of Resistance ...mentioning

confidence: 99%

What is the role of microbial biotechnology and genetic engineering in medicine?

Santos‐Beneit

2024

MicrobiologyOpen

View full text Add to dashboard Cite

Microbial products are essential for developing various therapeutic agents, including antibiotics, anticancer drugs, vaccines, and therapeutic enzymes. Genetic engineering techniques, functional genomics, and synthetic biology unlock previously uncharacterized natural products. This review highlights major advances in microbial biotechnology, focusing on gene‐based technologies for medical applications.

show abstract

Section: Bacteriophage‐based Therapies To Combat Forms Of Resistance ...mentioning

confidence: 99%

What is the role of microbial biotechnology and genetic engineering in medicine?

Santos‐Beneit

2024

MicrobiologyOpen

View full text Add to dashboard Cite

show abstract

“…The use of bacteriophages, which are viruses that attack and eliminate bacteria, set the groundwork for an innovative approach called bacteriophage therapy in treating bacterial infections. The use of bacteriophage therapy has regained attention as a promising substitute for antibiotics, especially in the face of AMR ( Usman et al, 2023 ). The application of bacteriophages in combating bacterial infections is not a novel idea, and the origins of research on bacteriophage therapy can be traced back to the beginning of the 1900s.…”

Section: Introductionmentioning

confidence: 99%

Crisis averted: a world united against the menace of multiple drug-resistant superbugs -pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal

Saeed,

Insaf,

Piracha

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

The efficacy of antibiotics and other antimicrobial agents in combating bacterial infections faces a grave peril in the form of antimicrobial resistance (AMR), an exceedingly pressing global health issue. The emergence and dissemination of drug-resistant bacteria can be attributed to the rampant overuse and misuse of antibiotics, leading to dire consequences such as organ failure and sepsis. Beyond the realm of individual health, the pervasive specter of AMR casts its ominous shadow upon the economy and society at large, resulting in protracted hospital stays, elevated medical expenditures, and diminished productivity, with particularly dire consequences for vulnerable populations. It is abundantly clear that addressing this ominous threat necessitates a concerted international endeavor encompassing the optimization of antibiotic deployment, the pursuit of novel antimicrobial compounds and therapeutic strategies, the enhancement of surveillance and monitoring of resistant bacterial strains, and the assurance of universal access to efficacious treatments. In the ongoing struggle against this encroaching menace, phage-based therapies, strategically tailored to combat AMR, offer a formidable line of defense. Furthermore, an alluring pathway forward for the development of vaccines lies in the utilization of virus-like particles (VLPs), which have demonstrated their remarkable capacity to elicit a robust immune response against bacterial infections. VLP-based vaccinations, characterized by their absence of genetic material and non-infectious nature, present a markedly safer and more stable alternative to conventional immunization protocols. Encouragingly, preclinical investigations have yielded promising results in the development of VLP vaccines targeting pivotal bacteria implicated in the AMR crisis, including Salmonella, Escherichia coli, and Clostridium difficile. Notwithstanding the undeniable potential of VLP vaccines, formidable challenges persist, including the identification of suitable bacterial markers for vaccination and the formidable prospect of bacterial pathogens evolving mechanisms to thwart the immune response. Nonetheless, the prospect of VLP-based vaccines holds great promise in the relentless fight against AMR, underscoring the need for sustained research and development endeavors. In the quest to marshal more potent defenses against AMR and to pave the way for visionary innovations, cutting-edge techniques that incorporate RNA interference, nanomedicine, and the integration of artificial intelligence are currently under rigorous scrutiny.

show abstract

Characterization and genome-informatic analysis of a novel lytic Pseudomonas mendocina phage vB_PmeS_STP12 suitable for phage therapy or biocontrol

Usman,

Christina

2024

Mol Biol Rep

View full text Add to dashboard Cite

Bacteriophage genome engineering for phage therapy to combat bacterial antimicrobial resistance as an alternative to antibiotics

Cited by 9 publications

References 82 publications

What is the role of microbial biotechnology and genetic engineering in medicine?

What is the role of microbial biotechnology and genetic engineering in medicine?

Crisis averted: a world united against the menace of multiple drug-resistant superbugs -pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal

Characterization and genome-informatic analysis of a novel lytic Pseudomonas mendocina phage vB_PmeS_STP12 suitable for phage therapy or biocontrol

Contact Info

Product

Resources

About